Caring for Pregnant Patients with HS

The presentation discusses the management of pregnant patients with hidradenitis suppurativa (HS), focusing on the unique challenges these patients face. HS predominantly affects women, often beginning around their 20s or 30s, making it crucial for healthcare providers to understand how this skin condition can influence pregnancy outcomes. Research indicates that women with HS may experience lower rates of live births, higher elective termination rates, and increased risks of adverse outcomes such as gestational hypertension and prematurity. The presenter emphasizes the need for collaboration with obstetricians to monitor these patients closely and address any modifiable risks. Although some might experience symptom relief during pregnancy, many will not, necessitating regular follow-up to adjust treatment as needed. Treatment options include topical agents like clindamycin and safe oral antibiotics during pregnancy. Biologics such as adalimumab and infliximab can also be considered due to low fetal exposure, with discussions about the timing of administration and possible immunosuppressive effects on newborns. The talk highlights treatments to avoid in pregnancy, including tetracyclines and hormonal therapies, and mentions potential procedural options that may be applicable for managing HS. Overall, the goal is to equip healthcare providers with the necessary tools and knowledge to effectively care for pregnant patients suffering from HS.